iron isomaltoside 1000
iron isomaltoside 1000 is a pharmaceutical drug with 19 clinical trials. Currently 1 active trials ongoing. Historical success rate of 92.3%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
12 of 15 finished
20.0%
3 ended early
1
trials recruiting
19
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma
HiFIT Study : Hip Fracture: Iron and Tranexamic Acid
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer
Clinical Trials (19)
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma
HiFIT Study : Hip Fracture: Iron and Tranexamic Acid
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer
Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.
Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage
Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion
Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients
Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery
Iron Replacement in Oesophagogastric Neoplasia
A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Treatment of Women After Severe Postpartum Haemorrhage
IV Iron Treatment of Restless Legs Syndrome
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease
Treatment of Women After Postpartum Haemorrhage
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD
All 19 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 19